OncoMatch/Clinical Trials/NCT07248956

Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma

Is NCT07248956 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Finolizumab and Albumin-Bound Paclitaxel /nab-Paclitaxel for hypopharyngeal carcinoma.

Phase 2RecruitingEye & ENT Hospital of Fudan UniversityNCT07248956Data as of May 2026

Treatment: Finolizumab · Albumin-Bound Paclitaxel /nab-Paclitaxel · Cisplatin — This is a multi-center, randomized controlled, prospective clinical study.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage III, IVA

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify